Trends in head and neck cancers in England from 1995 to 2011 and projections up to 2025

Oral Oncology

Volumn 51, Issue 4, 2015, Pages 341-348

  Louie, Karly S ^a   Mehanna, Hisham ^b   Sasieni, Peter ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Head and neck cancers; Human papillomavirus; Projections; Trends

Indexed keywords

WART VIRUS VACCINE;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PREVENTION; CANCER REGISTRY; CANCER RISK; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HYPOPHARYNX CANCER; LARYNX CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NASOPHARYNX CANCER; OROPHARYNX CANCER; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; SEXUALLY TRANSMITTED DISEASE; SMOKING; UNITED KINGDOM; VACCINATION; WART VIRUS; FORECASTING; OROPHARYNGEAL NEOPLASMS; REGISTER;

ENGLAND; FORECASTING; HUMANS; OROPHARYNGEAL NEOPLASMS; REGISTRIES;

EID: 84930703526     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2015.01.002     Document Type: Article

References (57)

1. Chaturvedi AK, Anderson WF, Lortet-Tieulent J, Curado MP, Ferlay J, Franceschi S, et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol 2013;31:4550-9.
2. Simard EP, Torre LA, Jemal A. International trends in head and neck cancer incidence rates: differences by country, sex and anatomic site. Oral Oncol 2014;50:387-403.
3. Mehanna H, Beech T, Nicholson T, El-Hariry I, McConkey C, Paleri V, et al. Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer-systematic review and meta-analysis of trends by time and region. Head Neck 2013;35:747-55.
4. Mehanna H, Jones TM, Gregoire V, Ang KK. Oropharyngeal carcinoma related to human papillomavirus. BmJ 2010;340:c1439.
5. Johnson AM, Mercer CH, Erens B, Copas AJ, McManus S, Wellings K, et al. Sexual behaviour in Britain: partnerships, practices, and HIV risk behaviours. Lancet 2001;358:1835-42.
6. Gillison ML, Alemany L, Snijders PJ, Chaturvedi A, Steinberg BM, Schwartz S, et al. Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis. Vaccine 2012;30(Suppl 5):F34-54.
7. Mitchell D, Audisio R, Cruickshank G, Cannon S, Gill T, Hayes A, et al. Boys in the UK should be offered vaccination against human papillomavirus (HPV). BmJ 2014;348:g3762.
8. Herrero R, Quint W, Hildesheim A, Gonzalez P, Struijk L, Katki HA, et al. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS One 2013;8:e68329.
9. Annual HPV vaccine coverage 2013 to 2014: by PCT, local authority and area team. . [accessed 15.12.14].
10. Vaccine Uptake in Children in Wales July to September 2014. [accessed 15.12.14].
11. Annual HPV vaccine coverage in Northern Ireland: 2013-2014. [accessed 15.12.14].
12. HPV immunisation Uptake Rates: HPV Immunisation Programme - School Year 2013/14. [accessed 15.12.14].
13. Office of National Statistics. 2010-based, National Population Projections; 2011. [accessed 26.11.12].
14. Ahmad AS, Parkin DM, Sasieni PD. Reply to 'comment on cancer incidence in the United Kingdom: projections to the year 2030'. Br J Cancer 2013;108:1215-7.
15. Oxford Cancer Intelligence Unit. Profile of head and neck cancers in England: incidence, mortality and survival; 2011.
16. Dal Maso L, Bosetti C, La Vecchia C, Franceschi S. Risk factors for thyroid cancer: an epidemiological review focused on nutritional factors. Cancer Causes Control 2009;20:75-86.
17. Goldenberg D, Lee J, Koch WM, Kim MM, Trink B, Sidransky D, et al. Habitual risk factors for head and neck cancer. Otolaryngol Head Neck Surg 2004;131:986-93.
18. HIV & STI Department. Centre for infectious disease surveillance and control, sexually transmitted infections in the UK. London, UK: Public Health England; 2012.
19. Waterhouse J, Muir C, Correa P, Powell Je. Cancer incidence in five continents. In: IARC, editor. Lyon; 1976. p. 456.
20. Mistry M, Parkin DM, Ahmad AS, Sasieni P. Cancer incidence in the United Kingdom: projections to the year 2030. Br J Cancer 2011;105:1795-803.
21. Sasieni PD. Age-period-cohort models in Stata. Stata J 2012;12:45-60.
22. Moller B, Fekjaer H, Hakulinen T, Tryggvadottir L, Storm HH, Talback M, et al. Prediction of cancer incidence in the Nordic countries up to the year 2020. Eur J Cancer Prev 2002;11(Suppl. 1):S1-S96.
23. Rutherford MJ, Thompson JR, Lambert PC. Projecting cancer incidence using age-period-cohort models incorporating restricted cubic splines. Int J Biostat 2012;8:33.
24. Blomberg M, Friis S, Munk C, Bautz A, Kjaer SK. Genital warts and risk of cancer: a Danish study of nearly 50, 000 patients with genital warts. J Infect Dis 2012;205:1544-53.
25. Schache AG, Liloglou T, Risk JM, Filia A, Jones TM, Sheard J, et al. Evaluation of human papilloma virus diagnostic testing in oropharyngeal squamous cell carcinoma: sensitivity, specificity, and prognostic discrimination. Clin Cancer Res 2011;17:6262-71.
26. Louie K, Olaleye O, Dunn J, Powell N, Sasieni P, Mehanna H. Epidemiology of human papilloma virus associated oropharyngeal cancer in England and Wales: Recent UK estimates in the last decade from the (PET-NECK) randomised controlled trial. In: The 4th world congress of the international academy of oral oncology (IAOO); May 15-18, 2013; Rhodes Island, Greece. OP025.
27. D'Souza G, Gross ND, Pai SI, Haddad R, Anderson KS, Rajan S, et al. Oral human papillomavirus (HPV) infection in HPV-positive patients with oropharyngeal cancer and their partners. J Clin Oncol 2014.
28. Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BmJ 2008;337:a769.
29. Canfell K, Chesson H, Kulasingam SL, Berkhof J, Diaz M, Kim JJ. Modeling preventative strategies against human papillomavirus-related disease in developed countries. Vaccine 2012;30(Suppl. 5):F157-67.
30. Bresse X, Goergen C, Prager B, Joura E. Universal vaccination with the quadrivalent HPV vaccine in Austria: impact on virus circulation, public health and cost-effectiveness analysis. Expert Rev Pharmacoecon Outcomes Res 2014;14:269-81.
31. Brisson M, Laprise JF, Drolet M, Van de Velde N, Franco EL, Kliewer EV, et al. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study. Vaccine 2013;31:3863-71.
32. Pearson AL, Kvizhinadze G, Wilson N, Smith M, Canfell K, Blakely T. Is expanding HPV vaccination programs to include school-aged boys likely to be value-for-money: a cost-utility analysis in a country with an existing schoolgirl program. BMC Infect Dis 2014;14:351.
33. Kim K, Amonkar MM, Hogberg D, Kasteng F. Economic burden of resected squamous cell carcinoma of the head and neck in an incident cohort of patients in the UK. Head Neck Oncol 2011;3:47.
34. Gulland A. Drug companies agree to cut price of HPV vaccine to developing countries to increase accessibility. BmJ 2013;346:f3025.
35. Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011;103:1444-51.
36. The Royal College of Radiologists, Clinical Oncology UK Workforce Report 2012;2012. [accessed July 2014].
37. Mehanna H, West CM, Nutting C, Paleri V. Head and neck cancer-Part 2: treatment and prognostic factors. BmJ 2010;341:c4690.
38. Shiraz F, Rahtz E, Bhui K, Hutchison I, Korszun A. Quality of life, psychological wellbeing and treatment needs of trauma and head and neck cancer patients. Br J Oral Maxillofac Surg 2014;52:513-7.
39. Cooper AF, Hankins M, Rixon L, Eaton E, Grunfeld EA. Distinct work-related, clinical and psychological factors predict return to work following treatment in four different cancer types. Psychooncology 2013;22:659-67.
40. National Institute for Clinical Excellence, Guidance on cancer services: improving outcomes in head and neck cancers - the manual; 2004. [accessed July 2014].
41. Elwood JM, Youlden DR, Chelimo C, Ioannides SJ, Baade PD. Comparison of oropharyngeal and oral cavity squamous cell cancer incidence and trends in New Zealand and Queensland, Australia. Cancer Epidemiol 2014;38:16-21.
42. Blomberg M, Nielsen A, Munk C, Kjaer SK. Trends in head and neck cancer incidence in Denmark, 1978-2007: focus on human papillomavirus associated sites. Int J Cancer 2011;129:733-41.
43. Braakhuis BJ, Visser O, Leemans CR. Oral and oropharyngeal cancer in The Netherlands between 1989 and 2006: increasing incidence, but not in young adults. Oral Oncol 2009;45:e85-9.
44. Johnson-Obaseki S, McDonald JT, Corsten M, Rourke R. Head and neck cancer in Canada: trends 1992 to 2007. Otolaryngol Head Neck Surg 2012;147:74-8.
45. Hocking JS, Stein A, Conway EL, Regan D, Grulich A, Law M, et al. Head and neck cancer in Australia between 1982 and 2005 show increasing incidence of potentially HPV-associated oropharyngeal cancers. Br J Cancer 2011;104:886-91.
46. Ioka A, Tsukuma H, Ajiki W, Oshima A. Trends in head and neck cancer incidence in Japan during 1965-1999. Jpn J Clin Oncol 2005;35:45-7.
47. Iyer NG, Kim L, Nixon IJ, Palmer F, Kraus D, Shaha AR, et al. Factors predicting outcome in malignant minor salivary gland tumors of the oropharynx. Arch Otolaryngol Head Neck Surg 2010;136:1240-7.
48. Brunner M, Koperek O, Wrba F, Erovic BM, Heiduschka G, Schoppper C, et al. HPV infection and p16 expression in carcinomas of the minor salivary glands. Eur Arch Otorhinolaryngol 2012;269:2265-9.
49. Isayeva T, Said-Al-Naief N, Ren Z, Li R, Gnepp D, Brandwein-Gensler M. Salivary mucoepidermoid carcinoma: demonstration of transcriptionally active human papillomavirus 16/18. Head Neck Pathol 2013;7:135-48.
50. Office of National Statistics, Population Estimates by Ethnic Group 2002-2009;2011. [accessed June 2014].
51. NHS Health and Social Care Information Centre, Health Survey for England 2004: The Health of MInority Ethnic Groups; 2005. [accessed July 2014].
52. Lee CH, Ko AM, Warnakulasuriya S, Ling TY, Rajapakse PS, et al. Population burden of betel quid abuse and its relation to oral premalignant disorders in South, Southeast, and East Asia: an Asian Betel-quid Consortium Study. Am J Public Health 2012;102:e17-24.
53. Maringe C, Mangtani P, Rachet B, Leon DA, Coleman MP, dos Santos Silva I. Cancer incidence in South Asian migrants to England, 1986-2004: unraveling ethnic from socioeconomic differentials. Int J Cancer 2013;132:1886-94.
54. Office of National Statistics, General lifestyle survey overview - a report on the 2011 general lifestyle survey. Published online March 7 2013.
55. Doobaree IU, Landis SH, Linklater KM, El-Hariry I, Moller H, Tyczynski J. Head and neck cancer in South East England between 1995-1999 and 2000-2004: an estimation of incidence and distribution by site, stage and histological type. Oral Oncol 2009;45:809-14.
56. Conway DI, Stockton DL, Warnakulasuriya KA, Ogden G, Macpherson LM. Incidence of oral and oropharyngeal cancer in United Kingdom (1990-1999) - recent trends and regional variation. Oral Oncol 2006;42:586-92.
57. Reddy VM, Cundall-Curry D, Bridger MW. Trends in the incidence rates of tonsil and base of tongue cancer in England, 1985-2006. Ann R Coll Surg Engl 2010;92:655-9.